Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sanpower and CITIC to Raise $2.9 Billion for Sanpower's Healthcare M&A

publication date: Jan 23, 2017
Sanpower Group has enlisted China's CITIC Bank, a state-owned investor, to raise $2.9 billion for a healthcare M&A fund, which will fund Sanpower's healthcare acquisitions. Already, Sanpower has committed $1.6 billion -- more than half the total -- to two big-dollar purchases: $820 million for prostate cancer immunotherapy company Dandreon and $781 million to purchase 65% of China Cord Blood. Sanpower already owns several China hospitals, and in 2014, it paid $70 million to acquire Natali, an Israeli home healthcare company. More details....

Stock Symbol: (NYSE: CO)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital